Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension

References

• Simonneau G, Montani D, Celermajer D, et al. Number 4 in the series “Proceedings of the 6th World Symposium on Pulmonary Hypertension” Edited by N. Galiè, V.V. McLaughlin, L.J. Rubin and G. Simonneau. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. doi:10.1183/13993003.01913-2018
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030. doi:10.1164/rccm.200510-1668OC
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–163. doi:10.1161/CIRCULATIONAHA.109.911818
   PubMed Web of Science ®Google Scholar
• Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–1665. doi:10.1056/NEJMra035488
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–349. doi:10.7326/0003-4819-115-5-343
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50:1700889. doi:10.1183/13993003.00889-2017
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549–555. doi:10.1183/09031936.00057010
   PubMed Web of Science ®Google Scholar
• Thenappan T, Shah SJ, Rich S, Tian L, Archer S, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35:1079–1087. doi:10.1183/09031936.00072709
   PubMed Web of Science ®Google Scholar
• Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest. 2012;141:642–650. doi:10.1378/chest.11-0969
   PubMed Web of Science ®Google Scholar
• Weatherald J, Boucly A, Chemla D, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation. 2018;137(7):693–704. doi:10.1161/CIRCULATIONAHA.117.029254
   PubMed Web of Science ®Google Scholar
• Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39:4175–4181. doi:10.1093/eurheartj/ehx257
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50:1700740. doi:10.1183/13993003.00740-2017
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122:164–172. doi:10.1161/CIRCULATIONAHA.109.898122
   PubMed Web of Science ®Google Scholar
• Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141:354–362. doi:10.1378/chest.11-0676
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Foreman AJ, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL) analysis. J Heart Lung Transplant. 2015;34:356–361. doi:10.1016/j.healun.2014.09.016
   PubMed Web of Science ®Google Scholar
• Anwar A, Ruffenach G, Mahajan A, Eghbali M, Umar S. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016;17:88. doi:10.1186/s12931-016-0396-6
   PubMed Web of Science ®Google Scholar
• Benedetto P, Guggino G, Manzi G, et al. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Res Ther. 2020;22:127. doi:10.1186/s13075-020-02218-8
   PubMed Web of Science ®Google Scholar
• Luk K, Ip C, Gong M, et al.; and International Health Informatics Study (IHIS) Network. A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. J Geriatr Cardiol. 2017;14(12):766–771. doi:10.11909/j.issn.1671-5411.2017.12.007.
   PubMedGoogle Scholar
• Nold-Petry CA, Nold MF, Zepp JA, Kim S-H, Voelkel NF, Dinarello CA. IL-32-dependent effects of IL-1 on endothelial cell functions. Proc Natl Acad Sci U S A. 2009;106(10):3883–3888. doi:10.1073/pnas.0813334106
   PubMed Web of Science ®Google Scholar
• Nold-Petry CA, Rudloff I, Baumer Y, et al. IL-32 promotes angiogenesis. J Immunol. 2014;192:589–602. doi:10.4049/jimmunol.1202802
   PubMed Web of Science ®Google Scholar
• Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol. 2009;157:527–536. doi:10.1111/j.1476-5381.2009.00240
   PubMed Web of Science ®Google Scholar
• Thenappan T, Ormiston M, Ryan J, Archer S. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:5492. doi:10.1136/bmj.j5492
   PubMed Web of Science ®Google Scholar
• Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D13–21. doi:10.1016/j.jacc.2013.10.035
   PubMed Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Humbert M. Current insights on the pathogenesis of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005;26(4):355–364. doi:10.1055/s-2005-916149
   PubMed Web of Science ®Google Scholar
• Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–927. doi:10.1161/CIRCULATIONAHA.109.933762
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard H, Nicolls M. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012;40:1555–1565. doi:10.1183/09031936.00046612
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Chabot F, Labarère J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J. 2014;43:915–917. doi:10.1183/09031936.00151313
   PubMed Web of Science ®Google Scholar
• Heresi GA, Aytekin M, Hammel JP, Wang S, Chatterjee S, Dweik R. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J. 2014;43:912–914. doi:10.1183/09031936.00164713
   PubMed Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185:311–321. doi:10.1164/rccm.201105-0927OC
   PubMed Web of Science ®Google Scholar
• Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respiratory Critical Care Med. 2012;186:261–272. doi:10.1164/rccm.201201-0164OC
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353(13):1412–1413. doi:10.1056/NEJMc051946
   PubMed Web of Science ®Google Scholar
• Speich R, Treder U, Domenighetti G, Huber LC, Ulrich S. Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension. Int J Clin Pharm. 2014;36(2):256–260. doi:10.1007/s11096-013-9881-x
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–1138. doi:10.1161/CIRCULATIONAHA.112.000765
   PubMed Web of Science ®Google Scholar
• Rodríguez‐Iturbe B, Pons H, Quiroz Y, Lanaspa MA, Johnson RJ. Autoimmunity in the pathogenesis of hypertension. Nat Rev Nephrol. 2014;10:56–62. doi:10.1038/nrneph.2013.248
   PubMed Web of Science ®Google Scholar
• Caillon A, Schiffrin EL. Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. Curr Hypertens Rep. 2016;18:21. doi:10.1007/s11906-016-0628-7
   PubMed Web of Science ®Google Scholar
• McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end‐organ damage. Circ Res. 2015;116:1022–1033. doi:10.1161/CIRCRESAHA.116.303697
   PubMed Web of Science ®Google Scholar
• Chen TH, Gona P, Sutherland PA, et al. Long‐term C‐reactive protein variability and prediction of metabolic risk. Am J Med. 2009;122:53–61. doi:10.1016/j.amjmed.2008.08.023
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Shiina K, Matsumoto‐Nakano C, et al. The contribution of inflammation to the development of hypertension mediated by increased arterial stiffness. J Am Heart Assoc. 2017;6:e005729. doi:10.1161/JAHA.117.005729;.
   PubMed Web of Science ®Google Scholar
• Mozos I, Malainer C, Horbańczuk J, et al. Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases. Front Immunol. 2017;8:1058. doi:10.3389/fimmu.2017.01058
   PubMed Web of Science ®Google Scholar
• Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118–1122. doi:10.1161/01.HYP.0000185463.27209.b0
   PubMed Web of Science ®Google Scholar
• Arnold N, Gori T, Schnabel R, et al. Relation between arterial stiffness and markers of inflammation and hemostasis data from the population-based gutenberg health study. Sci Rep. 2017;7:6346. doi:10.1038/s41598-017-06175-2
   PubMed Web of Science ®Google Scholar
• Nickel N, Yuan K, Dorfmuller P, et al. Beyond the Lungs: systemic Manifestations of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2020;201(2):148–157. doi:10.1164/rccm.201903-0656CI
   PubMed Web of Science ®Google Scholar
• Radchenko G, Zyvylo I, Titov E, Sirenko Y. Systemic arterial stiffness in new diagnosed idiopathic pulmonary arterial hypertension patients. Vasc Health Risk Manag. 2020;16:29–39. doi:10.2147/VHRM.S230041
   PubMed Web of Science ®Google Scholar
• Miyoshi T, Ito H. Assessment of arterial stiffness using the cardio-ankle vascular index. Pulse. 2016;4(1):11–23. doi:10.1159/000445214
   Google Scholar
• Guyatt G, Sullivan M, Thompson P, et al. The 6-minute walk: a new measure of exercise capacity in subjects with chronic heart failure. Can Med Assoc J. 1985;132:919–923.
   PubMed Web of Science ®Google Scholar
• ATS Statement. Guidelines for the six minute walk test. Am J Respir Crit Care Med. 2002;166:111–117. doi:10.1164/ajrccm.166.1.at1102
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Society Echocardiography. 2015;28(1):1–39. doi:10.1016/j.echo.2014.10.003
   PubMed Web of Science ®Google Scholar
• 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension. Eur Heart J. 2018;00:1–98. doi:10.1093/eurheartj/ehy339
   Google Scholar
• Fukuda-Denshi Company L. Tokyo, Japan. Available from: https://fukuda.com/products_category/vascular-screening/and.https://fukuda.com/wp-content/uploads/2020/07/VS-2000_Catalog_8Prev2.pdf. Accessed December 26, 2020.
   Google Scholar
• Cheuk-Kwan S. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness Integrated. Blood Pressure Control. 2013;6:27–38. doi:10.2147/IBPC.S34423
   PubMedGoogle Scholar
• Yambe T, Yoshizawa M, Saijo Y, et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother. 2004;58(Suppl 1):S95–S98. doi:10.1016/S0753-3322(04)80015-5
   PubMedGoogle Scholar
• Shimony A, Eisenberg MJ, Rudski LG, et al. Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension. Am J Cardiol. 2011;108:460–464. doi:10.1016/j.amjcard.2011.03.066
   PubMed Web of Science ®Google Scholar
• Anand V, Roy SS, Archer SL, et al. Trends and outcomes of pulmonary arterial hypertension-related hospitalizations in the United States: analysis of the nationwide inpatient sample database from 2001 through 2012. JAMA Cardiol. 2016;1:1021–1029. doi:10.1001/jamacardio.2016.3591
   PubMed Web of Science ®Google Scholar
• Hughes R, Tong J, Oates C, Lordan J, Corris PA. Evidence for systemic endothelial dysfunction in patients and first-order relatives with pulmonary arterial hypertension. Chest. 2005;128(6, Suppl):617S. doi:10.1378/chest.128.6_suppl.617S
   PubMed Web of Science ®Google Scholar
• Malenfant S, Brassard P, Paquette M, et al. Compromised cerebrovascular regulation and cerebral oxygenation in pulmonary arterial hypertension. J Am Heart Assoc. 2017;6:e006126. doi:10.1161/JAHA.117.006126
   PubMed Web of Science ®Google Scholar
• Nickel NP, de Jesus Perez VA, Zamanian RT, et al. Low-grade albuminuria in pulmonary arterial hypertension. Pulm Circ. 2019;9(2):1–9. doi:10.1177/2045894018824564
   Web of Science ®Google Scholar
• Riccieri V, Vasile M, Iannace N, et al. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. Rheumatology. 2013;52:1525–1528. doi:10.1093/rheumatology/ket168
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, Im H, Cao A, et al. RNA sequencing analysis detection of a novel pathway of endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192:356–366. doi:10.1164/rccm.201408-1528OC
   PubMed Web of Science ®Google Scholar
• Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012;5:336–343. doi:10.1161/CIRCGENETICS.111.961888
   PubMed Web of Science ®Google Scholar
• Desjardins M, Sidibé A, Fortier C, et al. Association of interleukin-6 with aortic stiffness in end-stage renal disease. JASH. 2018;12(1):5–13. doi:10.1016/j.jash.2017.09.013
   Web of Science ®Google Scholar
• Du B, Ouyang A, Eng J, Fleenor B. Aortic perivascular adipose-derived interleukin-6 contributes to arterial stiffness in low-density lipoprotein receptor deficient mice. Am J Physiol Heart Circ Physiol. 2015;308(11):H1382–H1390. doi:10.1152/ajpheart.00712.2014
   PubMed Web of Science ®Google Scholar
• Reiss A, Siegart N, De Leon J. Interleukin-6 in atherosclerosis: atherogenic or atheroprotective? Clin Lipidol. 2017;12(1):14–23. doi:10.1080/17584299.2017.1319787
   Google Scholar
• Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2008;33(2):318–324. doi:10.1183/09031936.00000508
   PubMed Web of Science ®Google Scholar
• Vakilian F, Attaran D, Shegofte M, Lari S, Ghare S. Assessment of thyroid function in idiopathic pulmonary hypertension. Res Cardiovasc Med. 2016;5(2):e29361. doi:10.5812/cardiovascmed.29361
   PubMedGoogle Scholar
• Li JH, Safford RE, Aduen JF, Heckman MG, Crook JE, Burger CD. Pulmonary hypertension and thyroid disease. Chest. 2007;132(3):793–797. doi:10.1378/chest.07-0366
   PubMed Web of Science ®Google Scholar
• Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist DeBakey Cardiovasc J. 2017;13:55–59. doi:10.14797/mdcj-13-2-55
   PubMedGoogle Scholar
• Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biomech. 1980;13:175–184. doi:10.1016/0021-9290(80)90191-8
   PubMed Web of Science ®Google Scholar
• Bramwell JC, Hill AV. The velocity of the pulse wave in man. Proc R Soc B Biol Sci. 1922;93:298–306. doi:10.1098/rspb.1922.0022
   Google Scholar
• Kubozono T, Miyata M, Ueyama K, et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J. 2007;71:89–94. doi:10.1253/circj.71.89
   PubMed Web of Science ®Google Scholar
• Schillaci G, Battista F, Settimi L, Anastasio F, Pucci G. Cardio-ankle vascular index and subclinical heart disease. Hypertens Res. 2015;38:68–73. doi:10.1038/hr.2014.138
   PubMed Web of Science ®Google Scholar
• Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J. 2007;71:1710–1714. doi:10.1253/circj.71.1710
   PubMed Web of Science ®Google Scholar
• Horinaka S, Yagi H, Ishimura K, et al. Cardio-ankle vascular index (CAVI) correlates with aortic stiffness in the thoracic aorta using ECG-gated multi-detector row computed tomography. Atherosclerosis. 2014;235:239–245.
   PubMed Web of Science ®Google Scholar
• Peled N, Shitrit D, Fox BD, et al. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol. 2009;36:970–975. doi:10.3899/jrheum.081088
   PubMed Web of Science ®Google Scholar
• Townsend RR, Wilkinson IB, Schiffrin EL, et al. Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension. 2015;66:698–722.
   PubMed Web of Science ®Google Scholar
• Chamorro N, Del Pozo R, García-Lucio J, et al. Peripheral arterial stiffness and endothelial dysfunction in pulmonary arterial hypertension. Eur Respir J. 2015;46:PA2452. doi:10.1183/13993003.congress-2015.PA2452
   Web of Science ®Google Scholar
• Sznajder M, Dzikowska-Diduch O, Kurnicka K, et al. Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension. Cardiol J. 2018;7:e009459. doi:10.5603/CJ.a2018.0109
   Google Scholar
• Hu Y, Li L, Shen L, Gao H. The relationship between arterial wall stiffness and left ventricular dysfunction. Neth Heart J. 2013;21(5):222–227. doi:10.1007/s12471-012-0353-z
   PubMed Web of Science ®Google Scholar
• Schillaci G, Mannarino MR, Pucci G, et al. Age-specific relationship of aortic pulse wave velocity with left ventricular geometry and function in hypertension. Hypertension. 2007;49(2):317–321. doi:10.1161/01.HYP.0000255790.98391.9b
   PubMed Web of Science ®Google Scholar
• Kim HL, Lim WH, Seo JB, et al. Association between arterial stiffness and left ventricular diastolic function in relation to gender and age. Medicine. 2017;96(1):e5783. doi:10.1097/MD.0000000000005783
   PubMed Web of Science ®Google Scholar
• Hoeper M, Boucly A, Sitbon O. Age, risk and outcomes in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51:1800629. doi:10.1183/13993003.00629-2018
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–223. doi:10.7326/0003-4819-107-2-216
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Huscher D, Pittrow D. Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol. 2016;203:612–613. doi:10.1016/j.ijcard.2015.11.001
   PubMed Web of Science ®Google Scholar
• Radegran G, Kjellstrom B, Ekmehag B, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014. Scand Cardiovasc J. 2016;50:243–250. doi:10.1080/14017431.2016.1185532
   PubMed Web of Science ®Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014;129(1):57–65. doi:10.1161/CIRCULATIONAHA.113.004526
   PubMed Web of Science ®Google Scholar
• Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation. 2015;132(25):2403–2411. doi:10.1161/CIRCULATIONAHA.115.018435
   PubMed Web of Science ®Google Scholar
• Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting hemodynamics in pulmonary arterial hypertension. Int J Cardiol. 2013;167(4):1193–1198. doi:10.1016/j.ijcard.2012.03.135
   PubMed Web of Science ®Google Scholar